BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1484673)

  • 1. Clinical experience with tissue plasminogen activator stored at -20 degrees C.
    Grewing R; Mester U; Löw M
    Ophthalmic Surg; 1992 Nov; 23(11):780-1. PubMed ID: 1484673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stability of tissue plasminogen activator (t-PA).
    Gaffney PJ; Templeman J; Curtis AD; Campbell PJ
    Thromb Haemost; 1983 Oct; 50(3):650-1. PubMed ID: 6685926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator: a new thrombolytic agent.
    Crabbe SJ; Cloninger CC
    Clin Pharm; 1987 May; 6(5):373-86. PubMed ID: 3117481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
    Carr ME; Krishnamurti C; Alving BM
    Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activation at low temperatures in plasma samples containing therapeutic concentrations of tissue-type plasminogen activator or other thrombolytic agents.
    Rijken DC; Seifried E; Barrett-Bergshoeff MM; Dooijewaard G
    Thromb Haemost; 1990 Aug; 64(1):47-52. PubMed ID: 2125758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator and penetrating keratoplasty.
    Heidemann DG; Williams GA; Blumenkranz MS
    Ophthalmic Surg; 1990 May; 21(5):364-5. PubMed ID: 2116614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for administration of tissue plasminogen activator.
    Topol EJ; Agnelli G
    Mol Biol Med; 1991 Apr; 8(2):219-34. PubMed ID: 1806764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tissue-type plasminogen activator].
    Turazza FM; Pogna M
    Medicina (Firenze); 1990; 10(1):75-8. PubMed ID: 2116566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA.
    Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ
    Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant tissue plasminogen activator: implications in therapy.
    Topol EJ
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):25-31. PubMed ID: 2508227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
    Colucci M; Paramo JA; Stassen JM; Collen D
    J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.